[1]. Paśko P, Rodacki T, Domagała-Rodacka R, Owczarek D. Interactions between medications employed in treating benign prostatic hyperplasia and food- A shortreview. Biomed Pharmacother. 2016 Oct; 83: 1141-1145.
[2]. Garg M, Kaur G, Malhotra V, Garg R. Histopathological spectrum of 364 prostatic specimens including immunohistochemistry with special reference to grey zone lesions. Prostate Int. 2013; 1(4): 146-51.
[3]. Fahmy O, Khairul-Asri MG, Schubert T, Renninger M, Stenzl A, Gakis G. Clinico-pathological features and prognostic value of incidental prostatic adenocarcinoma in radical cysto-prostatectomy specimens: a systematic review and meta-analysis of 13140 patients. J Urol. 2016 Aug 25; pii: S0022-5347(16): 31143-0.
[4]. Sui X, Hu Y, Zhang C, Pan H, Li D. Prostate cancer metastasis to the distal phalanx of the left hallux: The first confirmed case and literaturereview. Oncol Lett. 2016 Aug; 12(2): 1074-1078.
[5]. Guraya SS, Prayson RA. Metastatic prostatic adenocarcinoma with neuroendocrine differentiation to meningioma. J Clin Neurosci. 2016 Aug 5. pii: S0967-5868(16): 30304-6.
[6]. Helpap B. Differential diagnosis of glandular proliferations in the prostate: a conventional and immunohistochemical approach. Virchows Arch. 1998; 433: 397-405.
[7]. Seipel AH, Samaratunga H, Delahunt B, Wiklund P, Clements M, Egevad L. Immunohistochemistry of ductal adenocarcinoma of the prostate and adenocarcinomas of non-prostatic origin: a comparative study. APMIS. 2016 Apr; 124(4): 263-70.
[8]. Kryvenko ON, Williamson SR, Trpkov K, Gupta NS, Athanazio D, Selig MK, Smith PT, Magi-Galluzzi C, Jorda M Virchows Arch. Small cell-like glandular proliferation of prostate: a rare lesion not related to small cell prostate cancer. 2016 Oct 14.
[9]. Carter HB, Partin AW, Walsh PC, Trock BJ, Veltri RW, Nelson WG, Coffey DS, Singer EA. Gleason score 6 adenocarcinoma: should it be labeled as cancer? Epstein JI.J Clin Oncol. 2012 Dec 10; 30(35): 4294-6.
[10].Eggener SE. Risk of lymph node metastases in pathological gleason score≤6 prostate adenocarcinoma: Analysis of institutional and population-based databases. Urol Oncol. 2016 Sep 27. pii: S1078-1439(16): 30212-5. doi: 10.1016/j.urolonc.2016.08.004.
[11].Parimi V, Goyal R, Poropatich K, Yang, XJ. Neuroendocrine differentiation of prostate cancer: a review. Am J Clin Exp Urol. 2014; 2(4): 273-285.
[12].Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL. ISUP Grading Committee. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason grading of prostatic carcinoma. Am J Surg Pathol. 2005; 29(9): 1228-42
[13].Mildred B, Martens Jeremy H. Keller.routine immunohistochemical staining for high-molecular weight cytokeratin 34-β and α-methylacyl CoA racemase (P504S) in postirradiation prostate biopsies. Modern Pathology. 2006; 19: 287-290. doi:10.1038/modpathol.3800531.
[14].Beach R, Gown AM, de Peralta-Venturina MN, et al. P504S immunohistochemical detection in 405 prostatic specimens including 376 18-gauge needle biopsies. Am J Surg Pathol. 2002; 26: 1588-1596.
[15].Enciu M, Aşchie M, Boşoteanu M, Chisoi A, Rom J. Embryol M. Atypical adenomatous hyperplasia of the prostate mimicking adenocarcinoma lesion: case report and literature review. 2012; 53(4): 1093-6.
[16].Humphrey PA. Gleason grading and prognostic factors in carcinoma of the prostate. Modern Pathology. 2004; 17(3): 292-306.
[17].Seipel AH, Samaratunga H, Delahunt B, Wiklund F, Wiklund P, Lindberg J, Grönberg H, Egevad L. Immunohistochemical profile of ductal adenocarcinoma of the prostate. Virchows Arch. 2014 Nov; 465(5): 559-65.
[18].Golmohammadi R, Kamalimanesh B. ProtectiveEffect of ascorbicAcid on histology of purkinje neurons of cerebellum in pentylentetrazol-induced epileptic rats. Jmums.mazums. 2015; 25(123): 45-53.
[19].Golmohammadi R, Sabaghzadeh F, Mojadadi MS Effect of hydroalcoholic extract of Anethum graveolens leaves on the dentate gyrus of the hippocampus in the epileptic mice: a histopathological and immunohistochemical study. Res Pharm Sci. 2016 May-Jun; 11(3): 227-32.
[20].Golmohammadi R, Rakhshani MH, Moslem AR, Pejhan A. Prognostic role of PTEN gene expression and length of survival of breast cancer patients in the North East of Iran. Asian Pac J Cancer Prev. 2016; 17(S3): 305-9.
[21].Shah RB, Zhou M, LeBlanc M, Snyder M, Rubin MA: Comparison of the basal cell-specific markers, 34betaE12 and p63, in the diagnosis of prostate cancer. Am J Surg Pathol. 2002; 26(9): 1161-1168.
[22].Oliai BR, Kahane H, Epstein JI: Can basal cells be seen in adenocarcinoma of the prostate? An immunohistochemical study using HMWCK (34βE12) antibody. AM J Surg Pathol. 2002; 26: 1151-1160.
[23].Epstein JI, Egevad L, Humphrey PA, Montironi R. Members of the ISUP Immunohistochemistry in Diagnostic Urologic Pathology Group Best practices recommendations in the application of immunohistochemistry in the prostate: report from the International Society of Urologic Pathology consensus conference. Am J Surg Pathol. 2014 Aug; 38(8): e6-e19.
[24].Montironi R, Scarpelli M, Mazzucchelli R, Lopez-Beltran A, Santoni M, Briganti A, Montorsi F, Cheng L. Does prostate acinar adenocarcinoma with Gleason Score 3+3=6 have the potential to metastasize? Diagnostic Pathology. 2014; 19:190. http://www.diagnosticpathology.org/content/19/1/190
[25].Kumaresan K, Kakkar N, Verma A, Kumar Mandal A, Kumar Singh Sh, Joshi K. Diagnostic utility of α-methylacyl CoA racemase (P504S) & HMWCK in morphologically difficult prostate cancer. Diagnostic Pathology. 2010; 5: 83. http://www.diagnosticpathology.org/content/5/1/83.
[26].Seipel AH, Samaratunga H, Delahunt B, Wiklund F, Wiklund P, Lindberg J, Grönberg H, Egevad L. Immunohistochemical profile of ductal adenocarcinoma of the prostate. Virchows Arch. 2014 Nov; 465(5): 559-65..